E Jiménez-Varo, M Cañadas-Garre, C I Henriques, A M Pinheiro, M J Gutiérrez-Pimentel, M Á Calleja-Hernández
Vitamin K antagonists (VKAs) remain as the most prescribed drug for treatment and prevention of thrombotic disorders in many countries, despite the recent approval of the new oral anticoagulants (NOACs). Although effectiveness and safety of VKAs are tightly associated to maintaining the patient within the international normalised ratio (INR) therapeutic range (TWR), they have been likened to NOACs when patients are in good INR control (≥66% of TWR). Therefore, assessing the safety of patients should be a priority in the selection of the anticoagulation therapy...
September 2, 2014: Thrombosis and Haemostasis